P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This is a randomized, multi-center, double-blinded study in subjects with moderate to severe
acne vulgaris. Subjects eligible to enroll will be treated once or twice daily with 2
concentrations of a topical drug in development or a vehicle. Subjects will be treated for up
to 12 weeks.